Home Tags DS-8201

Tag: DS-8201

Breakthrough Therapy Designation for DS-8201 Confirms the Potential to Offer Substantial...

The U.S. Food and Drug Administration (FDA) earlier today confirmed that it has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate...

Pivotal Phase II Study of DS-8201 in Patients with HER2-Positive Metastatic...

Researchers at Daichi Sankyo initiation the DESTINY-Breast01, a pivotal phase II study evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting antibody-drug conjugate...

Nivolumab and DS-8201 to be Evaluated in HER2-Expressing Breast and Bladder...

Bristol-Myers Squibb and Daiichi Sankyo have agreed to collaborate in a clinical trial to evaluate the combination of Bristol-Myers Squibb’s immunotherapy nivolumab (Opdivo®) and...

Daiichi Sankyo Invests in the Future of Antibody-drug Conjugates

Daiichi Sankyo is making an initial Japanese ¥ 15 billion (US $ 135 million) investment to optimize and enhance its manufacturing capabilities to support...

X